Landmark pancreatic cancer drug shows potential against lung cancer too
2026-09-02 08:00Science🔥 28.9 heat score
1sources
1days unfolding
28.9heat score
5mentions
SummaryAI generated
The pancreatic cancer drug daraxonrasib demonstrated potential efficacy in small-scale clinical trials for patients with non-small cell lung cancer carrying RAS family mutations, with tumor shrinkage in over 30% of patients. This drug works by binding to the cyclic protein A and blocking the activity of the RAS protein. Previously, it increased the average survival period from 6.7 months to 13.2 months in 500 patients with advanced pancreatic cancer. The US FDA has approved its use for pancreatic cancer treatment ahead of time. Currently, larger-scale randomized controlled trials are being conducted to evaluate its efficacy and resistance mechanisms in lung cancer. The FDA will not approve its use for lung cancer treatment until the results of these studies are available.
The pancreatic cancer drug daraxonrasib (Rasonque) has shown potential efficacy in a small clinical trial against non-small cell lung cancer, with over 30% of patients harboring RAS family mutations experiencing tumor shrinkage. The drug acts as a "molecular glue" by binding to cyclophilin A, a cellular protein, forming a complex that blocks the interaction between normal and mutated RAS proteins and their chaperone proteins. In a prior study of 500 patients with advanced pancreatic cancer, daraxonrasib increased the average survival period from 6.7 to 13.2 months, leading the U.S. FDA to grant an accelerated approval on August 26. A larger-scale randomized controlled trial is currently underway to evaluate the efficacy and resistance mechanisms of daraxonrasib in non-small cell lung cancer. The U.S. FDA expects to wait for the results of this study before approving the drug for lung cancer treatment.